Abstract

EPH84 Burden of Respiratory Syncytial Virus in Children ≤ 2 Years of Age in Germany: Retrospective Analysis of Health Claims Data from 2014-2019

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Inpatient burden of respiratory syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019-2022.
Moritz Wick ... Mathieu Bangert
Influenza and other respiratory viruses | VOL. 17
Moritz Wick, et. al.Moritz Wick ... Mathieu Bangert
01 Nov 2023
EPH182 Inpatient Burden of Respiratory Syncytial Virus in Children ≤2 Years of Age in Germany: A Retrospective Analysis of Nationwide Hospitalization Data, 2019-2021
M Wick ... M Bangert
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 25
M Wick, et. al.M Wick ... M Bangert
01 Dec 2022
Review for "Inpatient burden of respiratory syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019–2022"
-
-
--
13 Jun 2023
Decision letter for "Inpatient burden of respiratory syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019–2022"
Benjamin Cowling
-
Benjamin Cowling Benjamin Cowling
29 Sep 2023
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
Correction.
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 23
--
01 Dec 2020
Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 23
--
01 Dec 2020
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group.
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 23
--
01 Nov 2020
Comprehensive Benefit-Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis.
Yulia Sidi ... Ofer Harel
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 23
Yulia Sidi, et. al.Yulia Sidi ... Ofer Harel
29 Oct 2020
View more papers